Top

Published in:

Open Access 01-12-2024 | Hypertension | Protocol

Screening for hypertension in adults: protocol for evidence reviews to inform a Canadian Task Force on Preventive Health Care guideline update

Authors: Nicole Shaver, Andrew Beck, Alexandria Bennett, Brenda J. Wilson, Chantelle Garritty, Melissa Subnath, Roland Grad, Navindra Persaud, Guylène Thériault, Jennifer Flemming, Brett D. Thombs, John LeBlanc, Janusz Kaczorowski, Peter Liu, Christopher E. Clark, Gregory Traversy, Eva Graham, Janusz Feber, Frans H. H. Leenen, Kamila Premji, Robert Pap, Becky Skidmore, Melissa Brouwers, David Moher, Julian Little

Published in: Systematic Reviews | Issue 1/2024

Abstract

Purpose

To inform updated recommendations by the Canadian Task Force on Preventive Health Care on screening in a primary care setting for hypertension in adults aged 18 years and older. This protocol outlines the scope and methods for a series of systematic reviews and one overview of reviews.

Methods

To evaluate the benefits and harms of screening for hypertension, the Task Force will rely on the relevant key questions from the 2021 United States Preventive Services Task Force systematic review. In addition, a series of reviews will be conducted to identify, appraise, and synthesize the evidence on (1) the association of blood pressure measurement methods and future cardiovascular (CVD)-related outcomes, (2) thresholds for discussions of treatment initiation, and (3) patient acceptability of hypertension screening methods. For the review of blood pressure measurement methods and future CVD-related outcomes, we will perform a de novo review and search MEDLINE, Embase, CENTRAL, and APA PsycInfo for randomized controlled trials, prospective or retrospective cohort studies, nested case–control studies, and within-arm analyses of intervention studies. For the thresholds for discussions of treatment initiation review, we will perform an overview of reviews and update results from a relevant 2019 UK NICE review. We will search MEDLINE, Embase, APA PsycInfo, and Epistemonikos for systematic reviews. For the acceptability review, we will perform a de novo systematic review and search MEDLINE, Embase, and APA PsycInfo for randomized controlled trials, controlled clinical trials, and observational studies with comparison groups. Websites of relevant organizations, gray literature sources, and the reference lists of included studies and reviews will be hand-searched. Title and abstract screening will be completed by two independent reviewers. Full-text screening, data extraction, risk-of-bias assessment, and GRADE (Grading of Recommendations Assessment, Development and Evaluation) will be completed independently by two reviewers. Results from included studies will be synthesized narratively and pooled via meta-analysis when appropriate. The GRADE approach will be used to assess the certainty of evidence for outcomes.

Discussion

The results of the evidence reviews will be used to inform Canadian recommendations on screening for hypertension in adults aged 18 years and older.

Systematic review registration

This protocol is registered on PROSPERO and is available on the Open Science Framework (osf.io/8w4tz).

Available only for authorised users

Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Smith N, et al. Screening for high blood pressure in adults: a systematic evidence review for the US Preventive Services Task Force. 2015.

World Health Organization. Hypertension. Available from: https://www.who.int/westernpacific/health-topics/hypertension. Cited 2021 Mar 22.

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899–911.PubMedPubMedCentralCrossRef

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903–13.CrossRef

Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596–624.PubMedCrossRef

Myers MG, Stergiou GS. White coat phenomenon. Hypertension. 2016;67(6):1111–3.PubMedCrossRef

Williams B, Mancia G, Rosei EA, Azizi M, Burnier M, Clement DL, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.PubMedCrossRef

National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. London: NICE; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547161/. NICE Guideline. Cited 2023 Apr 6.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-115.PubMed

10.

Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1223–49.CrossRef

11.

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.PubMedPubMedCentralCrossRef

12.

Finley CR, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S, et al. What are the most common conditions in primary care? Can Fam Physician. 2018;64:832.PubMedPubMedCentral

13.

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37 2020/02/05 ed.PubMedPubMedCentralCrossRef

14.

McAlister FA, Wilkins K, Joffres M, Leenen FHH, Fodor G, Gee M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011;183(9):1007–13.PubMedPubMedCentralCrossRef

15.

Gelfer M, Bell A, Petrella R, Campbell NRC, Cloutier L, Lindsay P, et al. Take urgent action diagnosing, treating, and controlling hypertension in older women. Can Fam Physician. 2020;66(10):726–31.PubMedPubMedCentral

16.

Leung AA, Williams JVA, McAlister FA, Campbell NRC, Padwal RS. Worsening hypertension awareness, treatment, and control rates in Canadian women between 2007 and 2017. Can J Cardiol. 2020;36(5):732–9.PubMedCrossRef

17.

Chamberlain AM, Cooper-DeHoff RM, Fontil V, Nilles EK, Shaw KM, Smith M, et al. Disruption in blood pressure control with the COVID-19 pandemic: the PCORnet Blood Pressure Control Laboratory. Mayo Clin Proc. 2023;98(5):662–75.PubMedCrossRef

18.

Dale CE, Takhar R, Carragher R, Katsoulis M, Torabi F, Duffield S, et al. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management. Nat Med. 2023;29(1):219–25.PubMedCrossRef

19.

Padwal RS, Bienek A, McAlister FA, Campbell NR, Outcomes research task force of the Canadian Hypertension Education P. Epidemiology of hypertension in Canada: an update. Can J Cardiol. 2016;32(5):687–94.PubMedCrossRef

20.

Campbell NR, Feldman RD. Hypertension in Canada and the global context. The wine is vintage and the glass is two-thirds full, but is the bottle empty? Can J Cardiol. 2016;32(5):609–11.PubMedCrossRef

21.

DeGuire J, Clarke J, Rouleau K, Roy J, Bushnik T. Blood pressure and hypertension. Statistics Canada; 2019 p. 14–21. Available from: https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2019002/article/00002-eng.pdf?st=rULafLTA. Report No.: Volume 30, no. 2.

22.

Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Primer. 2018;22(4):18014.CrossRef

23.

Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017;96(7):453–61.PubMed

24.

Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801–12.PubMedCrossRef

25.

Parikh NI, Pencina MJ, Wang TJ, Benjamin EJ, Lanier KJ, Levy D, et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med. 2008;148:102–10.PubMedCrossRef

26.

Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. The Lancet. 2001;358(9294):1682–6.CrossRef

27.

Lim NK, Son KH, Lee KS, Park HY, Cho MC. Predicting the risk of incident hypertension in a Korean middle-aged population: Korean genome and epidemiology study. J Clin Hypertens Greenwich. 2013;15(5):344–9.PubMedPubMedCentralCrossRef

28.

Mente A, O’Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, et al. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet. 2018;392(10146):496–506.PubMedCrossRef

29.

He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346:f1325.PubMedCrossRef

30.

He J, Whelton PK. Commentary: Salt intake, hypertension and risk of cardiovascular disease: an important public health challenge. Int J Epidemiol. 2002;31:327–31.PubMedCrossRef

31.

Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117–24.PubMedCrossRef

32.

Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 2009;302(4):401–11.PubMedPubMedCentralCrossRef

33.

Lee HA, Park H. Diet-related risk factors for incident hypertension during an 11-year follow-up: the Korean Genome Epidemiology Study. Nutrients. 2018;10(8):1077.PubMedPubMedCentralCrossRef

34.

Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, et al. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med. 2011;124(9):841–51.PubMedCrossRef

35.

Hegde SM, Solomon SD. Influence of physical activity on hypertension and cardiac structure and function. Curr Hypertens Rep. 2015;17(10):77.PubMedPubMedCentralCrossRef

36.

Wen H, Wang L. Reducing effect of aerobic exercise on blood pressure of essential hypertensive patients: a meta-analysis. Med Baltim. 2017;96(11):e6150.CrossRef

37.

Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2(2):e108–20.PubMedPubMedCentralCrossRef

38.

Fuchs FD, Chambless LE, Whelton PK, Nieto FJ, Heiss G. Alcohol consumption and the incidence of hypertension. Hypertension. 2001;37(5):1242–50.PubMedCrossRef

39.

Gao K, Shi X, Wang W. The life-course impact of smoking on hypertension, myocardial infarction and respiratory diseases. Sci Rep. 2017;7(1):4330.PubMedPubMedCentralCrossRef

40.

Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–84.PubMedCrossRef

41.

Leenen FHH, McInnis NH, Fodor G. Obesity and the prevalence and management of hypertension in Ontario. Canada Am J Hypertens. 2010;23(9):1000–6.PubMedCrossRef

42.

Gasevic D, Ross ES, Lear SA. Ethnic differences in cardiovascular disease risk factors: a systematic review of North American evidence. Can J Cardiol. 2015;31(9):1169–79.PubMedCrossRef

43.

Gagné T, Veenstra G. Inequalities in hypertension and diabetes in Canada: intersections between racial identity, gender, and income. Ethn Dis. 2017;27(4):371.PubMedPubMedCentralCrossRef

44.

Hozawa A, Ueshima H. Blood pressure differences by race: the importance of assessing lifestyle. Hypertens Res. 2009;32(12):1049–50.PubMedCrossRef

45.

Gopal DP, Francis R. Does race belong in the hypertension guidelines? J Hum Hypertens. 2020. Available from: http://www.nature.com/articles/s41371-020-00414-2. Cited 2021 Aug 25.

46.

Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother. 2018;52(11):1143–51.PubMedCrossRef

47.

Kurtz TW, DiCarlo SE, Pravenec M, Morris RC. No evidence of racial disparities in blood pressure salt sensitivity when potassium intake exceeds levels recommended in the US dietary guidelines. Am J Physiol-Heart Circ Physiol. 2021;320(5):H1903–18.PubMedPubMedCentralCrossRef

48.

Haroun MK, Jaar BG, Hoffman S, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County. Maryland J Am Soc Nephrol. 2003;14(11):2934–41.PubMedCrossRef

49.

Ridao N, Luño J, de Vinuesa SG, Gómez F, Tejedor A, Valderrábano F. Prevalence of hypertension in renal disease. Nephrol Dial Transplant. 2001;16(suppl_1):70–3.PubMedCrossRef

50.

Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am J Hypertens. 2010;23(2):116–24.PubMedCrossRef

51.

Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141–5.PubMedCrossRef

52.

Bhargava M, Ikram MK, Wong TY. How does hypertension affect your eyes? J Hum Hypertens. 2012;26(2):71–83.PubMedCrossRef

53.

Miller JB, Suchdev K, Jayaprakash N, Hrabec D, Sood A, Sharma S, et al. New developments in hypertensive encephalopathy. Curr Hypertens Rep. 2018;20(2):13.PubMedCrossRef

54.

Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–82.PubMedCrossRef

55.

World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: WHO; 2009. Available from: https://apps.who.int/iris/handle/10665/205781. Cited 2021 Dec 20.

56.

Lawes CMM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8.PubMedCrossRef

57.

University of Washington. GBD Compare. Institute for Health Metrics and Evaluation (IHME). Available from: https://vizhub.healthdata.org/gbd-compare/. Cited 2021 Jun 3.

58.

CDC. Centers for Disease Control and Prevention. 2020. Available from: https://www.cdc.gov/bloodpressure/CTA.htm. The surgeon general’s call to action to control hypertension | cdc.gov. Cited 2021 Jun 9.

59.

Bakris G, Hill M, Mancia G, Steyn K, Black HR, Pickering T, et al. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens. 2008;22(1):63–70.PubMedCrossRef

60.

Campbell NR, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, et al. Hypertension in diabetes: a call to action. Can J Cardiol. 2009;25(5):299–302.PubMedPubMedCentralCrossRef

61.

Luo D, Cheng Y, Zhang H, Ba M, Chen P, Li H, et al. Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis. BMJ. 2020;9:m3222.CrossRef

62.

Sawicka K, Szczyrek M, Jastrzębska I, Prasał M, Zwolak A, Daniluk J. Hypertension – the silent killer. J Pre Clin Clin Res. 2011;5(2):4.

63.

Kaczorowski J, Myers MG, Gelfer M, Dawes M, Mang EJ, Berg A, Grande CD, Kljujic D. How do family physicians measure blood pressure in routine clinical practice? National survey of Canadian family physicians. Can Fam Physician. 2017;63(3):e193–9.PubMedPubMedCentral

64.

George S, Anastasios K, Gianfranco P, Eoin O. Office blood pressure measurement. Hypertension. 2018;71(5):813–5.CrossRef

65.

Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J Hypertens. 2017;35(3):421–41.PubMedCrossRef

66.

Hwang KO, Aigbe A, Ju HH, Jackson VC, Sedlock EW. Barriers to accurate blood pressure measurement in the medical office. J Prim Care Community Health. 2018;9:215013271881692.CrossRef

67.

Thavarajah S, White WB, Mansoor GA. Terminal digit bias in a specialty hypertension faculty practice. J Hum Hypertens. 2003;17(12):819–22.PubMedCrossRef

68.

Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):351.PubMedPubMedCentralCrossRef

69.

Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. Hypertension. 2005;46(1):156–61.PubMedCrossRef

70.

Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens. 1997;15(4):357–64.PubMedCrossRef

71.

Clement DL, De Buyzere ML, De Bacquer DA, De Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407–15.PubMedCrossRef

72.

Chiolero A, Anker D. Screening interval: a public health blind spot. The Lancet Public Health. 2019;4(4):e171–2.PubMedCrossRef

73.

Garrison GM, Oberhelman S. Screening for hypertension annually compared with current practice. Ann Fam Med. 2013;11(2):116–21.PubMedPubMedCentralCrossRef

74.

Takahashi O, Glasziou PP, Perera R, Shimbo T, Fukui T. Blood pressure re-screening for healthy adults: what is the best measure and interval? J Hum Hypertens. 2012;26(9):540–6.PubMedCrossRef

75.

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;19(338):b1665–b1665.CrossRef

76.

Musini VM, Tejani AM, Bassett K, Puil L, Wright JM. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Hypertension Group, editor. Cochrane Database Syst Rev. 2019;(6). Available from: http://doi.wiley.com/10.1002/14651858.CD000028.pub3. Cited 2021 Mar 23.

77.

Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Hypertension Group, editor. Cochrane Database Syst Rev. 2017;(8). Available from: http://doi.wiley.com/10.1002/14651858.CD008276.pub2. Cited 2021 Mar 23.

78.

Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet. 2003;362(9395):1527–35.CrossRef

79.

Sacks FM, Bray GA, Iii ERM. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001;344(1):3–10.PubMedCrossRef

80.

Lin JS, O’Connor E, Whitlock EP, Beil TL. Behavioral counseling to promote physical activity and a healthful diet to prevent cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153(11):736.PubMedCrossRef

81.

Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Hypertension Group, editor. Cochrane Database Syst Rev. 2020. Available from: http://doi.wiley.com/10.1002/14651858.CD004022.pub5. Cited 2021 Mar 23.

82.

Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2017;319(2):115–6.CrossRef

83.

Lefebvre RC, Hursey KG, Carleton RA. Labeling of participants in high blood pressure screening programs: implications for blood cholesterol screenings. Arch Intern Med. 1988;148(9):1993–7.PubMedCrossRef

84.

Haase CB, Gyuricza JV, Brodersen J. New hypertension guidance risks overdiagnosis and overtreatment. BMJ. 2019;12:l1657.CrossRef

85.

Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012;28(3):270–87.PubMedCrossRef

86.

Lindsay P, Connor Gorber S, Joffres M, Birtwhistle R, McKay D, Cloutier L. Recommendations on screening for high blood pressure in Canadian adults. Can Fam Physician. 2013;59(9):927–33.PubMedPubMedCentral

87.

Levine M, Neary J, Raina P, Ciliska D, Hammill A, Gauld M, et al. Screening for hypertension. Hamilton: McMaster University; 2014. Available from: https://canadiantaskforce.ca/guidelines/published-guidelines/hypertension/.

88.

Siu AL, U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2015;163(10):778–86.PubMedCrossRef

89.

Guirguis-Blake JM, Evans CV, Webber EM, Coppola EL, Perdue LA, Weyrich MS. Screening for hypertension in adults: an updated systematic evidence review for the US preventive services task force. 2021. p. 218. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-review/hypertension-in-adults-screening.

90.

US Preventive Services Task Force. Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2021;325(16):1650.CrossRef

91.

Canadian Task Force on Preventive Health Care. Canadian Task Force on Preventive Health Care Procedure Manual. 2014. Available from: https://canadiantaskforce.ca/methods/.

92.

Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). 2021. Available from: Cochrane 2021. www.training.cochrane.org/handbook.

93.

GRADE Working Group. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013. Available from: https://gdt.gradepro.org/app/handbook/handbook.html.

94.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.CrossRef

95.

Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(1):28.PubMedCrossRef

96.

Pollock M, Fernandes RM, Becker LA, Pieper D, Hartling L. Chapter V: Overviews of reviews. In: Cochrane handbook. Available from: https://training.cochrane.org/handbook/current/chapter-v.

97.

Pollock A, Campbell P, Brunton G, Hunt H, Estcourt L. Selecting and implementing overview methods: implications from five exemplar overviews. Syst Rev. 2017;6(1):145.PubMedPubMedCentralCrossRef

98.

Gates M, Gates A, Guitard S, Pollock M, Hartling L. Guidance for overviews of reviews continues to accumulate, but important challenges remain: a scoping review. Syst Rev. 2020;9(1):254.PubMedPubMedCentralCrossRef

99.

McKenzie JE, Brennan SE. Overviews of systematic reviews: great promise, greater challenge. Syst Rev. 2017;6(1):185, s13643-017-0582–8.CrossRef

100.

National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Evidence review for initiating treatment. 2019. Available from: https://www.nice.org.uk/guidance/ng136/evidence/c-initiating-treatment-pdf-6896748208. Report No.: NICE guideline NG136.

101.

Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400.PubMedCrossRef

102.

McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6.PubMedCrossRef

103.

CADTH. Grey matters: a practical tool for searching health-related grey literature. 2018. Available from: https://www.cadth.ca/resources/finding-evidence. Cited 2019 Apr 25.

104.

Clyne B, Walsh KA, O’Murchu E, Sharp MK, Comber L, O’ Brien KK, et al. Using preprints in evidence synthesis: commentary on experience during the COVID-19 pandemic. J Clin Epidemiol. 2021. Available from: https://www.sciencedirect.com/science/article/pii/S0895435621001530. Cited 2021 May 20.

105.

The EndNote Team. EndNote. Philadelphia: Clarivate Analytics; 2020.

106.

Evidence Partners. DistillerSR. Ottawa; 2011. Available from: https://www.evidencepartners.com/.

107.

Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries: the evolution of a rapid review approach. Syst Rev. 2012;1(1):10.PubMedPubMedCentralCrossRef

108.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.

109.

Pieper D, Antoine SL, Mathes T, Neugebauer EAM, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368–75.PubMedCrossRef

110.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(366):l4898.CrossRef

111.

Higgins JPT, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane.org.

112.

Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. http://handbook.cochrane.org/.

113.

Balshem H, Stevens A, Ansari M, Norris S, Kansagara D, Shamliyan T, et al. Finding grey literature evidence and assessing for outcome and analysis reporting biases when comparing medical interventions: AHRQ and the Effective Health Care Program. In: Methods guide for effectiveness and comparative effectiveness reviews. Rockville: Agency for Healthcare Research and Quality (US); 2013. Available from: http://www.ncbi.nlm.nih.gov/books/NBK174882/. AHRQ Methods for Effective Health Care. Cited 2018 Jun 20.

114.

Higgins J, Green S. Chapter 16: Special topics in statistics. In: The cochrane collaboration cochrane handbook for systematic reviews of interventions. 2011.

115.

Wells G, Shea BJ, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Cited 2019 Nov 20.

116.

Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6.PubMedCrossRef

117.

Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;21(358):j4008.CrossRef

118.

U.S. Preventive Services Task Force. Procedure manual. 2015. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual. Cited 2021 Mar 18.

119.

Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66(2):158–72.PubMedCrossRef

120.

Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles—continuous outcomes. J Clin Epidemiol. 2013;66(2):173–83.PubMedCrossRef

121.

Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;16(368):l6890.CrossRef

122.

Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. Lancaster: ESRC Methods Programme; 2006. Available from: https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/fhm/dhr/chir/NSsynthesisguidanceVersion1-April2006.pdf. Cited 2021 Mar 30.

123.

Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol. 2011;64(11):1187–97.PubMedCrossRef

124.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557.PubMedPubMedCentralCrossRef

125.

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.PubMedCrossRef

126.

Sutton A, Abrams KR, Jones DR, Sheldon T, Song F. Methods for meta-analysis in medical research. Chichester. Wiley; 2000. p. 3.

127.

Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions version 62 (updated February 2021). 2021. Available from: https://training.cochrane.org/handbook/current/chapter-10. Cited 2021 Mar 9.

128.

Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101–5.PubMedPubMedCentralCrossRef

129.

Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine. 2019;98(23):e15987.PubMedPubMedCentralCrossRef

130.

Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351–75.PubMedCrossRef

131.

Jadad AR, Cook DJ, Browman GP. A guide to interpreting discordant systematic reviews. Can Med Assoc J. 1997;156(10):6.

132.

Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311–6.PubMedCrossRef

133.

Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.PubMedCrossRef

134.

Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2015;68(11):1312–24.PubMedCrossRef

135.

Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62–70.PubMedCrossRef

136.

Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences—risk of bias and indirectness. J Clin Epidemiol. 2019;1(111):94–104.CrossRef

137.

Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences—inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;1(111):83–93.CrossRef

138.

Cochrane Effective Practice and Organisation of Care (EPOC). Reporting the effects of an intervention in EPOC reviews. EPOC resources for review authors. 2018. Available from: https://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources-for-authors2017/how_to_report_the_effects_of_an_intervention.pdf.

139.

Santesso N, Glenton C, Dahm P, Garner P, Akl E, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2019;119:126–35.PubMedCrossRef

140.

Murad MH, Mustafa RA, Schünemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85–7.PubMedPubMedCentralCrossRef

141.

Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE working group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;1(87):4–13.CrossRef

142.

Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G, et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol. 2021;137:163–75.PubMedCrossRef

143.

Alonso-Coello P, Schünemann HJ, Moberg J, Romina BP, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.PubMedCrossRef

144.

Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;30:i2089.CrossRef

145.

Bougioukas KI, Liakos A, Tsapas A, Ntzani E, Haidich AB. Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. J Clin Epidemiol. 2018;93:9–24.PubMedCrossRef

Title: Screening for hypertension in adults: protocol for evidence reviews to inform a Canadian Task Force on Preventive Health Care guideline update
Authors: Nicole Shaver
Andrew Beck
Alexandria Bennett
Brenda J. Wilson
Chantelle Garritty
Melissa Subnath
Roland Grad
Navindra Persaud
Guylène Thériault
Jennifer Flemming
Brett D. Thombs
John LeBlanc
Janusz Kaczorowski
Peter Liu
Christopher E. Clark
Gregory Traversy
Eva Graham
Janusz Feber
Frans H. H. Leenen
Kamila Premji
Robert Pap
Becky Skidmore
Melissa Brouwers
David Moher
Julian Little
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Hypertension
Hypertension
Blood Pressure Measurement
Published in: Systematic Reviews / Issue 1/2024
Electronic ISSN: 2046-4053
DOI: https://doi.org/10.1186/s13643-023-02392-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Screening for hypertension in adults: protocol for evidence reviews to inform a Canadian Task Force on Preventive Health Care guideline update

Abstract

Purpose

Methods

Discussion

Systematic review registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Discussion

Systematic review registration

Please log in to get access to this content

Other articles of this Issue 1/2024

Correction: Protocol for spatial prediction of soil transmitted helminth prevalence in the Western Pacific region using a meta‑analytical approach

Protocol for a systematic review and meta-analysis of the prevalence of mental illness among nursing home residents

Self-reporting of psychoneurophysical (PNP) symptoms in adults with four chronic diseases: a protocol for a scoping review

Assessing risk of bias in the meta-analysis of round 1 of the Health Care Innovation Awards

Impact of health system strengthening interventions on child survival in sub-Saharan Africa: a systematic review protocol

Indigenous approaches to health assessment: a scoping review protocol